Management Using the Latest Technologies in Resource-limited Settings to Optimize Combination Therapy After Viral Failure

Not Applicable

• Conditions: Health Condition 1: null- HIV 1 infection

• Registration Number: CTRI/2018/05/014223
• Lead Sponsor: IH DAIDS

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: Closed to Recruitment of Participants
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

HIV-1 infection

Any previous combination of ARV treatment at any time with at least one regimen that contained one NNRTI and two NRTIs which was replaced with a PI-based regimen because of virologic, immunologic, or clinical treatment failure, or because of toxicity

Exclusion Criteria

Pregnancy or breast-feeding.

Known allergy/sensitivity or any hypersensitivity to components of study drugs or their formulation.

Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.

Serious illness requiring systemic treatment and/or hospitalization until candidate either completes therapy or is clinically stable on therapy, in the opinion of the site investigator, for at least 7 days prior to study entry.

Concurrent illness or condition that would compromise the ability to take study medication, follow the protocol, or that would make participation not in the best interest of the participant, per the site investigator.

Requirement for taking any of the prohibited medications with the selected ARV study regimen, or within 14 days prior to study entry.

Active tuberculosis (TB) or rifampin exposure less than 2 weeks prior to study entry.

Study & Design

• Study Type: Interventional
• Study Design: Not specified